Table 1

Profile of the patients

PatientDiagnosisAge at BMT (years)Age at menarche (years)Age at study (years)TBI (Gy)TAI (Gy)ChemotherapycGVHD
1AA4.512.815.98CY
2AA4.912.815.08CY
3CML5.311.014.412Ara-C, VP16
4ALL5.711.416.212VP16
5CML6.411.019.312CY, Ara-C
6ALL7.313.316.012Ara-C, VP16
7NHL7.514.015.812CY, VP16
8AML7.910.819.012CY, Ara-C
9ALL8.213.315.112Ara-C, VP16
10ALL9.013.316.012Ara-C, VP16
11AA9.712.322.68CY+
12NHL10.013.818.012Ara-C, VP16
13ALL4.616.012CY, Ara-C
14Fanconi8.419.96CY, ALG+
15AML11.122.612CY, Ara-C+
16AML12.321.312Ara-C, VP16
17AML15.024.612Ara-C, VP16
18AML15.323.412Ara-C, VP16
  • AA, aplastic anaemia; CML, chronic myelogenous leukaemia; ALL, acute lymphoblastic leukaemia; NHL, non-Hodgkin’s lymphoma; AML, acute myeloid leukaemia; Fanconi, Fanconi’s anaemia; BMT, bone marrow transplantation; TBI, total body irradiation; TAI, thoraco-abdominal irradiation; CY, cyclophosphamide; Ara-C, cytosine arabinoside; VP16, etoposide; ALG, antilymphocyte globulin; cGVHD, chronic graft versus host disease.